Fibrinogen, Factor VII and Plasminogen Activator Inhibitor-1 Genotypes and the Risk of Coronary Artery Disease.
- Author:
Hyun Kyung KIM
1
;
Kyung Soon SONG
;
Sun Ha JEE
;
Won Hm SHIM
;
Jung Shik SHIN
Author Information
1. Department of Clinical Pathology, College of Medicine, Yonsei University, Seoul, Korea. kssong@yumc.yonsei.ac.kr
- Publication Type:Original Article
- Keywords:
Fibrinogen;
Factor VII;
PAI-1;
Polymorphism;
Coronary artery disease
- MeSH:
Alleles;
Arteries;
Cardiovascular Diseases;
Case-Control Studies;
Coronary Artery Disease*;
Coronary Vessels*;
Factor VII*;
Fibrinogen*;
Genotype*;
Humans;
Hypertension;
Logistic Models;
Plasma;
Plasminogen Activator Inhibitor 1;
Plasminogen Activators*;
Plasminogen*;
Risk Factors
- From:Korean Journal of Hematology
2001;36(1):79-89
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: The aims of this study were to investigate the extent to which specific known polymorphisms of fibrinogen, factor VII (FVII) and PAI-1 genes are associated with their respective plasma levels. And also we examined whether these genotypes were linked to coronary artery disease (CAD). METHOD: We performed a case-control study of 165 patients which included 156 CAD and 9 peripheral artery obstructive disease and 188 healthy controls without a history of cardiovascular disease. The four polymorphisms of fibrinogen (Beta-455G/A, beta448Arg/Lys), FVII (353Arg/Gln) and PAI-1 (4G/5G) gene were measured, together with their plasma levels. RESULTS: There was a difference between patients and controls in the frequency of the fibrinogen beta448Lys allele (0.206 vs 0.106, P< 0.001), but there were no significant frequency differences in fibrinogen beta-455A (0.537 vs 0.529), FVII 353Gln (0.079 vs 0.080) and PAI-1 4G (0.146 vs 0.113) Allele. Plasma fibrinogen level was higher in patients (372.8+/-112.0 mg/ dL) than in controls (300.4+/-70.9 mg/dL) and patients with genotype beta448LysLys (457.8+/-134.4 mg/dL) or beta448ArgLys (397.3+/-120.8 mg/dL) had higher fibrinogen levels than those with 448ArgArg (354.9+/-102.3 mg/dL). Using multivariate logistic regression, the beta448 ArgLys or LysLys genotype was associated with over twice the risk of CAD (odds ratio 2.25) compared with the beta448ArgArg genotype. Hypertension is more potent risk factor for the person who has the beta448Lys allele of fibrinogen. CONCLUSION: These data provide evidence that a polymorphism of the fibrinogen beta488Arg/ Lys is associated with an increased risk of CAD and that hypertension is more potent risk factor for CAD in person who have the beta488Lys allele of fibrinogen.
